Legislators call HHS to action on Xtandi march-in rights

Nicole DeFeudis

Editor

More than two dozen lawmakers are putting renewed pressure on the federal government to use its march-in rights to lower the price of prostate cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Legislators call HHS to action on Xtandi march-in rights

Nicole DeFeudis

Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

Leg­is­la­tors call HHS to ac­tion on Xtan­di march-in rights

Editor

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Legislators call HHS to action on Xtandi march-in rights